BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 857 filers reported holding BAXTER INTL INC in Q3 2013. The put-call ratio across all filers is 0.73 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2019 | $830,000 | -19.3% | 10,133 | -19.8% | 0.00% | 0.0% |
Q1 2019 | $1,028,000 | -61.4% | 12,640 | -63.4% | 0.00% | -57.1% |
Q3 2018 | $2,665,000 | -96.8% | 34,572 | -97.0% | 0.01% | -97.1% |
Q2 2018 | $83,787,000 | +14.0% | 1,134,719 | +0.4% | 0.24% | +12.4% |
Q1 2018 | $73,528,000 | +28.2% | 1,130,496 | +27.4% | 0.22% | +33.7% |
Q4 2017 | $57,365,000 | -0.4% | 887,451 | -3.4% | 0.16% | -3.0% |
Q3 2017 | $57,624,000 | +352.3% | 918,309 | +336.3% | 0.17% | +342.1% |
Q2 2017 | $12,741,000 | +10.6% | 210,457 | -5.3% | 0.04% | +11.8% |
Q1 2017 | $11,521,000 | -83.8% | 222,150 | -78.6% | 0.03% | -81.1% |
Q1 2015 | $71,212,000 | -31.9% | 1,039,594 | -27.1% | 0.18% | -32.1% |
Q4 2014 | $104,570,000 | -18.9% | 1,426,794 | -20.5% | 0.26% | -18.0% |
Q3 2014 | $128,884,000 | -54.6% | 1,795,794 | -54.3% | 0.32% | -0.3% |
Q2 2014 | $283,964,000 | +89.7% | 3,927,588 | +93.1% | 0.32% | -5.0% |
Q1 2014 | $149,666,000 | +21.1% | 2,034,057 | +14.5% | 0.34% | +24.0% |
Q4 2013 | $123,542,000 | +5.9% | 1,776,300 | +0.0% | 0.28% | +2.2% |
Q3 2013 | $116,633,000 | +382.7% | 1,775,500 | +409.0% | 0.27% | +380.4% |
Q2 2013 | $24,161,000 | – | 348,800 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Soditic Asset Management LLP | 147,620 | $7,951,000 | 9.91% |
NUANCE INVESTMENTS, LLC | 5,429,702 | $292,444,000 | 6.51% |
Endurant Capital Management LP | 245,093 | $13,201,000 | 4.30% |
Veritas Asset Management LLP | 8,589,401 | $462,625,000 | 3.83% |
GENERATION INVESTMENT MANAGEMENT LLP | 11,876,040 | $639,644,000 | 3.80% |
Sivik Global Healthcare LLC | 120,000 | $6,463,000 | 3.59% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 480,500 | $25,880,000 | 3.31% |
Integral Health Asset Management, LLC | 300,000 | $16,158,000 | 3.14% |
Boothe Investment Group, Inc. | 89,078 | $4,798,000 | 3.11% |
Glenview Capital Management | 2,257,019 | $121,563,000 | 3.04% |